Novavax (NVAX) is a leading biotechnology business based in the US. It opened the day at $8.00 after a previous close of $8.00. During the day the price has varied from a low of $7.76 to a high of $8.16. The latest price was $8.06 (25 minute delay). Novavax is listed on the NASDAQ and employs 1,543 staff. All prices are listed in US Dollars.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Open | $0.00 |
|---|---|
| High | $0.00 |
| Low | $0.00 |
| Close | $0.00 |
| Previous close | $0.00 |
| Change | $0.00 |
| Change % | N/A% |
| Volume | 0 |
| 52-week range | $3.53 - $23.86 |
|---|---|
| 50-day moving average | $11.35 |
| 200-day moving average | $10.01 |
| Wall St. target price | $16.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.43 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.06 from 2024-11-19
| 1 week (2024-11-14) | 11.63% |
|---|---|
| 1 month (2024-10-21) | -20.51% |
| 3 months (2024-08-21) | -37.71% |
| 6 months (2024-05-21) | -45.94% |
| 1 year (2023-11-21) | 50.65% |
|---|---|
| 2 years (2022-11-21) | -57.47% |
| 3 years (2021-11-19) | 192.34 |
| 5 years (2019-11-21) | 111.55% |
| Revenue TTM | $885.2 million |
|---|---|
| Gross profit TTM | $-156,045,000 |
| Return on assets TTM | -10.76% |
| Return on equity TTM | -898.2% |
| Profit margin | -32.18% |
| Book value | $-3.29 |
| Market Capitalization | $1.2 billion |
TTM: trailing 12 months
We're not expecting Novavax to pay a dividend over the next 12 months.
Novavax's shares were split on a 1:20 basis on 9 May 2019 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.
Over the last 12 months, Novavax's shares have ranged in value from as little as $3.5324 up to $23.8599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 2.088. This would suggest that Novavax's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Novavax, Inc. , a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.